6 completed, 5 terminated, 2 unknown, 1 withdrawn. 10 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Terminated 4, Unknown 1 |
| Phase 3 | 5 | Terminated 2, Completed 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow visilizumab: new trials by email Literature Review of visilizumab trials Research Report on visilizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML Visilizumab - Immunotherapy, Refractory Leukemia | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 30 | 2021-05-01 | 2021-12-03 |
| Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation Visilizumab, Tacrolimus, Methotrexate - Graft Versus Host Disease | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 8 | 2007-12-01 | 2014-07-18 |
| An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis Visilizumab (Nuvion®; HuM291) - Ulcerative Colitis | Terminated | PDL BioPharma, Inc. | 300 | 2006-09-01 | 2008-08-05 | |
| Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study visilizumab - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Facet Biotech | 25 | 2006-08-01 | 2012-03-12 |
| Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC) Visilizumab - Ulcerative Colitis | Phase 2 | Terminated | Abbott | 38 | 2006-04-01 | 2012-04-27 |
| A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis visilizumab - Ulcerative Colitis | Phase 2 / Phase 3 | Terminated | Facet Biotech | 127 | 2006-02-01 | 2012-03-12 |
| Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease Visilizumab - Crohn's Disease | Phase 2 | Completed | Facet Biotech | 18 | 2005-02-01 | 2012-03-07 |
| Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease Visilizumab - Crohn's Disease | Phase 2 | Completed | Facet Biotech | 18 | 2005-02-01 | 2012-03-07 |
| Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis Visilizumab - Severe Ulcerative Colitis | Phase 1 / Phase 2 | Completed | Facet Biotech | 144 | 2004-01-01 | 2012-03-09 |
| Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease Visilizumab - Graft-vs-Host Disease | Phase 2 | Unknown | Fred Hutchinson Cancer Center | 80 | 2002-03-01 | 2005-06-24 |
| Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease Visilizumab - Graft vs Host Disease | Phase 1 / Phase 2 | Completed | Facet Biotech | 34 | 2002-03-01 | 2012-03-13 |
| Research Study in Patients With Severe Ulcerative Colitis Visilizumab - Ulcerative Colitis | Phase 2 / Phase 3 | Completed | Facet Biotech | 20 | 2002-03-01 | 2012-03-07 |
| Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma visilizumab - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | Stanford University | 2001-04-01 | 2013-05-15 | |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis Visilizumab (HuM291; Nuvion®) - Intravenous Steroid-Refractory Ulcerative Colitis | Phase 3 | Withdrawn | Facet Biotech | 150 | 2009-06-25 |
Colitis, Ulcerative (7) · Graft vs Host Disease (3) · Colitis (2) · Crohn Disease (2) · Leukemia (2) · Lymphoma (2) · Anemia, Aplastic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Gastrointestinal Diseases (1) · Hematologic Neoplasms (1) · Immunoblastic Lymphadenopathy (1) · Intestinal Diseases (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Large-Cell, Anaplastic (1)
Facet Biotech (8) · Abbott (1) · Fred Hutchinson Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · PDL BioPharma, Inc. (1) · Stanford University (1) · The First Affiliated Hospital of Soochow University (1)
United States (12) · Canada (4) · Australia (3) · Austria (3) · Belgium (3) · Czechia (3) · France (3) · Germany (3) · Hungary (3) · Italy (3) · Netherlands (3) · Norway (3) · Ukraine (3) · Croatia (2) · Israel (2)
Han Yue, Ph.D (1) · Lia Perez, MD (1) · Mihail Obrocea, MD (1) · Youn H. Kim, MD (1)
PMID 17920064, PMID 19714757, PMID 20947884, PMID 21874061
2005 (1), R01CA132197 (1)